Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Lenacapavir: a first-in-class HIV-1 capsid inhibitor.

Current opinion in HIV and AIDS

Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS.
PMID: 34871187
Curr Opin HIV AIDS. 2022 Jan 01;17(1):15-21. doi: 10.1097/COH.0000000000000713.

PURPOSE OF REVIEW: This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle.RECENT FINDINGS: Lenacapavir demonstrated picomolar potency in vitro with no cross...

Cite
Dvory-Sobol H, Shaik N, Callebaut C, et al. Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr Opin HIV AIDS. 2022;17(1):15-21doi: 10.1097/COH.0000000000000713.
Dvory-Sobol, H., Shaik, N., Callebaut, C., & Rhee, M. S. (2022). Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Current opinion in HIV and AIDS, 17(1), 15-21. https://doi.org/10.1097/COH.0000000000000713
Dvory-Sobol, Hadas, et al. "Lenacapavir: a first-in-class HIV-1 capsid inhibitor." Current opinion in HIV and AIDS vol. 17,1 (2022): 15-21. doi: https://doi.org/10.1097/COH.0000000000000713
Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS. Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr Opin HIV AIDS. 2022 Jan 01;17(1):15-21. doi: 10.1097/COH.0000000000000713. PMID: 34871187.
Copy Download .nbib Format: NLM
Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials.

Hepatology research : the official journal of the Japan Society of Hepatology

Asahina Y, Liu CJ, Gane E, Itoh Y, Kawada N, Ueno Y, Youn J, Wang CY, Llewellyn J, Matsuda T, Gaggar A, Mo H, Dvory-Sobol H, Crans G, Chuang WL, Chen PJ, Enomoto N.
PMID: 32614468
Hepatol Res. 2020 Oct;50(10):1109-1117. doi: 10.1111/hepr.13546. Epub 2020 Aug 11.

AIM: The combination of ledipasvir and sofosbuvir (LDV/SOF) has been approved for the treatment of various hepatitis C virus (HCV) genotypes across many countries. This article presents an integrated analysis of three prospective phase II/III trials in the Asia-Pacific...

Cite
Asahina Y, Liu CJ, Gane E, et al. Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials. Hepatol Res. 2020;50(10):1109-1117doi: 10.1111/hepr.13546.
Asahina, Y., Liu, C. J., Gane, E., Itoh, Y., Kawada, N., Ueno, Y., Youn, J., Wang, C. Y., Llewellyn, J., Matsuda, T., Gaggar, A., Mo, H., Dvory-Sobol, H., Crans, G., Chuang, W. L., Chen, P. J., & Enomoto, N. (2020). Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials. Hepatology research : the official journal of the Japan Society of Hepatology, 50(10), 1109-1117. https://doi.org/10.1111/hepr.13546
Asahina, Yasuhiro, et al. "Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials." Hepatology research : the official journal of the Japan Society of Hepatology vol. 50,10 (2020): 1109-1117. doi: https://doi.org/10.1111/hepr.13546
Asahina Y, Liu CJ, Gane E, Itoh Y, Kawada N, Ueno Y, Youn J, Wang CY, Llewellyn J, Matsuda T, Gaggar A, Mo H, Dvory-Sobol H, Crans G, Chuang WL, Chen PJ, Enomoto N. Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials. Hepatol Res. 2020 Oct;50(10):1109-1117. doi: 10.1111/hepr.13546. Epub 2020 Aug 11. PMID: 32614468.
Copy Download .nbib Format: NLM
The Future of HCV Therapy: NS4B as an Antiviral Target.

Viruses

Dvory-Sobol H, Pang PS, Glenn JS.
PMID: 21157574
Viruses. 2010 Nov;2(11):2481-92. doi: 10.3390/v2112481. Epub 2010 Nov 10.

Chronic hepatitis C virus (HCV) infection is a major worldwide cause of liver disease, including cirrhosis and hepatocellular carcinoma. It is estimated that more than 170 million individuals are infected with HCV, with three to four million new cases...

Cite
Dvory-Sobol H, Pang PS, Glenn JS. The Future of HCV Therapy: NS4B as an Antiviral Target. Viruses. 2010;2(11):2481-92doi: 10.3390/v2112481.
Dvory-Sobol, H., Pang, P. S., & Glenn, J. S. (2010). The Future of HCV Therapy: NS4B as an Antiviral Target. Viruses, 2(11), 2481-92. https://doi.org/10.3390/v2112481
Dvory-Sobol, Hadas, et al. "The Future of HCV Therapy: NS4B as an Antiviral Target." Viruses vol. 2,11 (2010): 2481-92. doi: https://doi.org/10.3390/v2112481
Dvory-Sobol H, Pang PS, Glenn JS. The Future of HCV Therapy: NS4B as an Antiviral Target. Viruses. 2010 Nov;2(11):2481-92. doi: 10.3390/v2112481. Epub 2010 Nov 10. PMID: 21157574; PMCID: PMC3000685.
Copy Download .nbib Format: NLM
The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment.

Hepatology communications

Gane EJ, Metivier S, Nahass R, Ryan M, Stedman CA, Svarovskaia ES, Mo H, Doehle B, Dvory-Sobol H, Hedskog C, Lin M, Brainard DM, Yang JC, McHutchison JG, Sulkowski M, Younes Z, Lawitz E.
PMID: 29404477
Hepatol Commun. 2017 Jun 22;1(6):538-549. doi: 10.1002/hep4.1060. eCollection 2017 Aug.

S282T in NS5B is the primary amino acid substitution associated with resistance to sofosbuvir (SOF) but has rarely been detected in patients treated with a SOF-based regimen. Here, the emergence and fitness of the S282T substitution in virologic failure...

Cite
Gane EJ, Metivier S, Nahass R, et al. The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. Hepatol Commun. 2017;1(6):538-549doi: 10.1002/hep4.1060.
Gane, E. J., Metivier, S., Nahass, R., Ryan, M., Stedman, C. A., Svarovskaia, E. S., Mo, H., Doehle, B., Dvory-Sobol, H., Hedskog, C., Lin, M., Brainard, D. M., Yang, J. C., McHutchison, J. G., Sulkowski, M., Younes, Z., & Lawitz, E. (2017). The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. Hepatology communications, 1(6), 538-549. https://doi.org/10.1002/hep4.1060
Gane, Edward J, et al. "The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment." Hepatology communications vol. 1,6 (2017): 538-549. doi: https://doi.org/10.1002/hep4.1060
Gane EJ, Metivier S, Nahass R, Ryan M, Stedman CA, Svarovskaia ES, Mo H, Doehle B, Dvory-Sobol H, Hedskog C, Lin M, Brainard DM, Yang JC, McHutchison JG, Sulkowski M, Younes Z, Lawitz E. The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. Hepatol Commun. 2017 Jun 22;1(6):538-549. doi: 10.1002/hep4.1060. eCollection 2017 Aug. PMID: 29404477; PMCID: PMC5678900.
Copy Download .nbib Format: NLM
Correction for Han et al., ".

Journal of clinical microbiology

Han B, Parhy B, Lu J, Zhou E, Hsieh D, Camus G, Martin R, Svarovskaia ES, Mo H, Dvory-Sobol H.
PMID: 32580966
J Clin Microbiol. 2020 Jun 24;58(7). doi: 10.1128/JCM.00857-20. Print 2020 Jun 24.

No abstract available.

Cite
Han B, Parhy B, Lu J, et al. Correction for Han et al., ". J Clin Microbiol. 2020;58(7)doi: 10.1128/JCM.00857-20.
Han, B., Parhy, B., Lu, J., Zhou, E., Hsieh, D., Camus, G., Martin, R., Svarovskaia, E. S., Mo, H., & Dvory-Sobol, H. (2020). Correction for Han et al., ". Journal of clinical microbiology, 58(7), . https://doi.org/10.1128/JCM.00857-20
Han, Bin, et al. "Correction for Han et al., "." Journal of clinical microbiology vol. 58,7 (2020). doi: https://doi.org/10.1128/JCM.00857-20
Han B, Parhy B, Lu J, Zhou E, Hsieh D, Camus G, Martin R, Svarovskaia ES, Mo H, Dvory-Sobol H. Correction for Han et al., ". J Clin Microbiol. 2020 Jun 24;58(7). doi: 10.1128/JCM.00857-20. Print 2020 Jun 24. PMID: 32580966; PMCID: PMC7315032.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries